MKN-28 Xenograft Model Service for Gastric Cancer

The MKN-28 Xenograft Model Service for Gastric Cancer provides a robust, well-characterized preclinical platform for evaluating therapeutic efficacy against well-differentiated gastric adenocarcinoma. At Alfa Cytology, we specialize in delivering high-quality, clinically relevant xenograft models tailored to accelerate your oncology drug development pipeline, offering end-to-end study design, tumor monitoring, and endpoint analysis with rigorous scientific oversight.

Overview of MKN-28 Xenograft Model for Gastric Cancer

The MKN-28 cell line was originally established from a well-differentiated tubular adenocarcinoma of the stomach in a 37-year-old male patient of Japanese origin. It exhibits adherent, epithelial-like morphology with preserved intestinal differentiation characteristics, including well-developed junctional complexes and apical-basolateral polarity. Genetically, MKN-28 harbors mutations in both the p53 tumor suppressor gene and the APC gene, while displaying microsatellite stable (MSS) status and a doubling time of approximately 28-32 hours under standard culture conditions. These molecular features make it particularly suitable for studying Wnt/beta-catenin signaling disruption, Helicobacter pylori-host interactions, and the effects of CagA oncoprotein on epithelial junctional architecture.

In vivo, MKN-28 xenografts consistently form solid, well-differentiated adenocarcinomas in immunodeficient mice, with histological concordance to the original primary tumor---a feature rarely observed among gastric cancer cell lines. The model demonstrates robust tumorigenicity and predictable growth kinetics, supporting its use in pharmacokinetic/pharmacodynamic studies, combination therapy screening, and biomarker validation for gastric cancer drug candidates.

Figure 1. Comparison of growth and morphological characteristics in different models. (Zheng, Wenhui, et al., 2025)

Cell Line Information: MKN-28

The following table summarizes the key characteristics of the MKN-28 human gastric cancer cell line:

Our Services

Alfa Cytology leverages the MKN-28 xenograft model as a cornerstone of its gastric cancer preclinical service portfolio, combining validated cell line authentication, standardized tumor implantation protocols, and comprehensive endpoint analysis to generate reproducible, publication-ready data that supports IND-enabling studies and translational oncology research.

Workflow of MKN-28 Xenograft Model Construction

Construction of the MKN-28 xenograft model follows a standardized, GLP-compliant workflow designed to ensure tumor engraftment consistency, animal welfare compliance, and data reproducibility. The process encompasses cell line qualification, animal preparation, tumor implantation, longitudinal monitoring, and terminal endpoint analysis.

1. Step 1: Cell Line Authentication and Expansion: MKN-28 cells are recovered from cryogenic storage and expanded under standardized culture conditions. Prior to inoculation, cells undergo STR profiling for identity confirmation, mycoplasma testing, and viability assessment to ensure high-quality, uncontaminated inoculum.
2. Step 2: Animal Selection and Acclimation: Immunodeficient mice (e.g., NOD-SCID or nude mice, 6-8 weeks old) are acquired from accredited vendors and acclimated for a minimum of five days. Baseline body weights and health status are recorded prior to study initiation.
3. Step 3: Tumor Cell Inoculation: Exponentially growing MKN-28 cells are harvested, washed, and resuspended in a 1:1 mixture of serum-free RPMI-1640 and Matrigel. A standardized cell suspension (typically 5 x 10^6 cells in 100-200 microL) is injected subcutaneously into the right flank of each mouse using aseptic technique.
4. Step 4: Tumor Monitoring and Randomization: Tumor growth is monitored twice weekly via electronic caliper measurements in two perpendicular dimensions. Tumor volume is calculated using the modified ellipsoid formula (V = 0.5 x length x width^2). Upon reaching a mean tumor volume of 100-150 mm^3, mice are randomized into treatment and vehicle control groups.
5. Step 5: Dosing and Treatment Administration: Test articles are administered according to the study protocol via the designated route (oral gavage, intraperitoneal, or intravenous injection). Dosing solutions are prepared fresh, and administration volumes are adjusted based on individual body weights.
6. Step 6: Longitudinal Assessment: Throughout the treatment phase, tumor dimensions, body weights, and clinical signs are recorded at defined intervals. Blood samples may be collected for pharmacokinetic analysis, and tumor growth inhibition (TGI) is calculated relative to the vehicle control group.
7. Step 7: Endpoint Analysis and Sample Collection: At study termination, mice are humanely euthanized. Tumors are excised, weighed, and photographed. Tissue samples are processed for histopathology (H&E staining, IHC), molecular profiling (Western blot, qPCR, RNA-seq), and biomarker analysis as specified in the study plan.

Figure 2: Schematic workflow illustrating the derivation and construction of the MKN-28 Xenograft Model at Alfa Cytology.

Case Study-MKN-28 Xenograft Model Development

In a representative preclinical engagement, MKN-28 cells were successfully engrafted in NOD-SCID mice with 100% take rate and predictable tumor growth kinetics. Tumors reached the target volume within 10-14 days post-inoculation, exhibiting well-differentiated adenocarcinoma histology consistent with the parental cell line. Treatment with a candidate therapeutic agent resulted in dose-dependent tumor growth inhibition, with the high-dose cohort achieving statistically significant reduction in tumor burden compared to vehicle controls. Pharmacodynamic analysis of excised tumors confirmed target engagement and downstream pathway modulation, supporting the model's utility for mechanism-of-action studies and dose-selection strategies in gastric cancer drug development.

Why Choose Alfa Cytology?

Alfa Cytology is committed to delivering scientifically rigorous, customizable preclinical oncology services that accelerate therapeutic discovery. Our MKN-28 xenograft model service is distinguished by the following advantages:

• Validated cell line authentication via STR profiling and routine mycoplasma screening to ensure model integrity.
• Standardized, reproducible tumor engraftment protocols with documented historical control data for robust statistical power.
• Flexible study designs accommodating single-agent, combination, and dose-escalation paradigms tailored to client objectives.
• Comprehensive endpoint analysis including tumor growth inhibition, survival analysis, histopathology, and molecular biomarker quantification.
• GLP-compliant data packages and detailed study reports suitable for regulatory submissions and peer-reviewed publications.
• Dedicated project management with PhD-level scientific consultation to guide study design, data interpretation, and next-step recommendations.

Contact Us

Ready to advance your gastric cancer therapeutic program with a validated MKN-28 xenograft model? Please reach out to us today via our inquiry form or email to learn more about our MKN-28 Xenograft Model services.

For research use only. Not intended for any clinical use.